Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer, and the only type of breast tumor still lacking a targeted treatment. New research pinpoints a JAK2-specific inhibitor as a potential targeted therapy for TNBC. This material relates to a paper that appeared in the April 13, 2016, issue of Science Translational Medicine, published by AAAS. The paper, by J.M. Balko at Vanderbilt University in Nashville, Tenn., and colleagues was titled, "Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence."
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.